PRE

Analyst Note: PRE (Prenetics Global Limited)

Date: 2026-06-20 Current Price: $20.50

1. Structural Readiness

Conservative Entry: Not yet defined (awaiting breakout confirmation) Aggressive/Pre-Breakout Entry: $20.50 (Current Price) Breakout Level: Not yet defined. Extension: Not applicable (Price is at the entry zone of the forming structure, not extended). ATR Context: Current ATR is 7.5% (Very High).

2. Thesis Layer

Thesis Classification: TACTICAL / SETUP-LED Macro Thesis: None. Assessment: As of 2026-06-20, there is no named secular macro thesis driving this name. The investment case is strictly tactical, derived from the quality of the technical setup combined with the fundamental acceleration of the business model. We are judging this name solely on its setup quality and the execution of its specific business fundamentals, without attributing it to a broader market theme.

3. Business Overview

Company: Prenetics Global Limited (PRE) Industry: Consumer Health & Wellness / Genetic Testing Business Model: PRE operates a dual-engine model: a legacy genetic testing platform and a rapidly scaling direct-to-consumer (DTC) subscription brand, IM8, co-founded with David Beckham.

Key Fundamentals (as of 2026-06-20):

• Revenue Acceleration: Management raised full-year 2026 IM8 revenue guidance to $190 million–$210 million, up from a prior range of $180 million–$200 million (Source: Earnings Transcript, 2026-05-14).
• Growth Trajectory: For Q2 2026, IM8 is expected to contribute $44 million–$46 million of total revenue, representing approximately 33% sequential quarterly growth in IM8 revenue alone (Source: Earnings Transcript, 2026-05-14).
• Subscription Stickiness: Active subscribers reached 82,000, with 93% of IM8 revenue derived from subscriptions (Source: Earnings Transcript, 2026-05-14).
• Product Expansion: Management announced the launch of three new SKUs in Q4 2026 (hydration, creatine, kids' gummies), projecting these to add $178–$378 of incremental second-year revenue per customer (Source: Earnings Transcript, 2026-05-14).
• Global Reach: The company is shipping to 43 countries, delivering approximately 150,000 servings daily (Source: Earnings Transcript, 2026-05-14).
• Unit Economics: Current cohorts are tracking toward an implied 12-month Lifetime Value (LTR) of $900–$1,100, significantly higher than the $571 delivered on mature cohorts (Source: Earnings Transcript, 2026-05-14).
• Financial Health: The company reported a net loss of $38.7 million for the fiscal year ended December 31, 2025, narrowing from $49.8 million in 2024 and $64.8 million in 2023 (Source: SEC Filing, 2026-04-30).
• Cost Structure: Selling and marketing expenses for FY2025 were $35.5 million, representing 38.5% of revenue from continuing operations (Source: SEC Filing, 2026-04-30).

4. Archetype and Conviction

Archetype: Growth Leader Rationale: PRE fits the "Growth Leader" archetype due to the rapid scaling of the IM8 brand, the high sequential growth rates (33% QoQ), and the expansion of the total addressable market (TAM) into new categories (hydration, creatine). The business is transitioning from a pure-play genetic testing firm to a diversified consumer health leader.

Conviction Stack:

• Thesis Strength: Moderate. The lack of a named macro thesis limits the "secular" tailwind, but the tactical setup is strong.
• Evidence Quality: High. Management has provided specific, quantified guidance for 2026, including revenue ranges, subscriber counts, and LTR projections.
• Structural Quality: Mixed. While revenue is growing, the company remains in a loss-making phase ($38.7M loss in 2025), though the loss is narrowing. The high marketing spend (38.5% of revenue) indicates a heavy investment in growth, which is typical for this archetype but carries execution risk.
• Rerating Potential: High, contingent on the successful launch of the new Q4 2026 products and the realization of the higher LTR metrics.

Valuation Context: The current price of $20.50 reflects the market's pricing of the 2026 guidance. The very high ATR (7.5%) suggests the market is pricing in significant volatility, likely due to the binary nature of the new product launches and the transition to profitability.

5. Invalidations, Strengths, and Gaps

What Would Strengthen the Case:

• Confirmation of the Q4 2026 product launch dates and immediate sell-through data exceeding the $178–$378 incremental revenue per customer projection.
• Further narrowing of the net loss in the next quarterly report, moving closer to GAAP profitability.

What Would Invalidate the Case:

• Regulatory hurdles in the 43 countries where the company operates, specifically regarding the new SKUs (hydration, creatine, gummies).
• A significant increase in customer acquisition costs or a drop in the 93% subscription retention rate.

Gaps in Evidence:

• Profitability Timeline: While losses are narrowing, there is no specific management guidance on the *date* or *quarter* when the company expects to reach GAAP profitability.
• Channel Mix: The reliance on Google and Facebook for digital advertising is a known risk (Source: SEC Filing, 2026-04-30), but there is no evidence provided on the diversification of these channels or the impact of potential platform policy changes.
• Operational Complexity: The SEC filing notes "significant operational complexity" (Source: SEC Filing, 2026-04-30), but there is no specific data on how this complexity is being managed or mitigated in the 2026 operational plan.

PRIVATE ANALYST CALL

Judgment: Speculative Confidence: medium Key evidence: 33% sequential quarterly growth in IM8 revenue; raised full-year 2026 IM8 guidance to $190M-$210M; active subscribers at 82,000 with 93% subscription revenue mix. Key risks: Very high ATR (7.5%) indicating elevated volatility; reliance on digital advertising platforms (Google/Facebook) for customer acquisition; continued net losses despite revenue growth; regulatory and operational complexity in 43 countries. Sizing hint: Position size should be reduced relative to a confirmed breakout setup due to the "forming" state and high volatility; treat as a tactical satellite holding. Expected path: Management expects the new Q4 2026 product launches to drive incremental LTR; the setup requires a price breakout above resistance to confirm the trend continuation. Expected horizon: 3 to 6 months for the setup to resolve into a confirmed breakout or invalidation.